New therapy for inflammatory bowel flares up

Main Category: Crohn's / IBD
Article Date: 24 Oct 2005 - 0:00 PDT

email to a friend   printer friendly   opinions  

Inflammatory bowel disorders may be due to excessive responses to antigens present in normal bacteria. In a paper appearing online on October 20 in advance of print publication of the November issue of the Journal of Clinical Investigation, Stefan Fichtner-Feigl and colleagues from the NIH successfully treat both murine colitis and murine Crohn disease with NF-kappaB decoy oligodeoxynucleotides.

The authors find that blockade of NF-kappaB activity is useful for both major forms of inflammatory bowel disease. This suggests a new therapeutic approach for treating human inflammatory bowel disorders.

TITLE: Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappaB decoy oligonucleotides

View the PDF of this article at: the-jci.org/article.php?id=24792

Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
jci.org

• Additional
• References
• Citations